![]() Image created from image crediting (Image by Unknown Owner) Details DMCA | "Patients are looking for safe and low-cost choices in their management of cancer," she told BBC News. "Intravenous vitamin C has that potential based on our basic science research and early clinical data." One potential hurdle is that pharmaceutical companies are unlikely to fund trials of intravenous vitamin C because there is no ability to patent natural products. "Because vitamin C has no patent potential, its development will not be supported by pharmaceutical companies," said lead researcher Qi Chen. "We believe that the time has arrived for research agencies to vigorously support thoughtful and meticulous clinical trials with intravenous vitamin C." |





